

GeNeuro to Host Conference Call and Webcast Today Following the Presentation of Promising Post-Hoc Analyses at the MSParis2017 Congress

**Conference call and webcast scheduled today
at 2:00 pm CET / 09:00 am EDT**

Geneva, Switzerland, 30 October 2017 at 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, reported promising post-hoc analyses of six-month data from CHANGE-MS Phase 2b study at MSParis2017 on Saturday October 28th and will hold a conference call and webcast today.

GeNeuro management will hold a conference call and webcast **today at 2:00 pm CET / 09:00 am EDT** in English to review post-hoc analyses which showed, at Week 24, anti-inflammatory effect in active patients and remyelination at the highest (18 mg/kg) of the three doses tested.

Jesús Martin-Garcia, CEO of GeNeuro, and the company management, will deliver a brief presentation, followed by a Q&A session.

Investors and analysts may participate via the following number:
+33 (0)1 72 00 15 10 or +41 225809022

PIN Code: 55743324#

The webcast can be followed live online via the link:

<http://www.anywhereconference.com?UserAudioMode=DATA&Name=&Conference=135311331&PIN=55743324>

Following the call, a replay will be available for 90 days. To access the replay, please dial:

- USA: +1 877 64 230 18
- United-Kingdom: +44 2033679460
- France: +33 1 72 00 15 00

PIN Code: 311331#

An archive of the webcast will be available on Geneuro's website, under the "Investors" section at geneuro.com.

About GeNeuro

GeNeuro's mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis or Type 1 diabetes, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has 30 employees and rights to 16 patent families protecting its technology.

For more information, visit: www.geneuro.com.

Contacts

GeNeuro

Jesús Martin-Garcia
Chairman and CEO
+41 22 552 4800
investors@geneuro.com

NewCap (France)

Julien Perez (investors)
+33 1 44 71 98 52
Nicolas Merigeau (media)
+33 1 44 71 94 98
geneuro@newcap.eu

Halsin Partners

Mike Sinclair (media)
+44 20 7318 2955
msinclair@halsin.com

LifeSci Advisors

Chris Maggos (investors)
+1 646 597 6970
+41 79 367 6254
chris@lifesciadvisors.com

Disclaimer

This press release contains certain forward - looking statements and estimates concerning GeNeuro's financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words such as "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "is designed to," "may," "might," "plan," "potential," "predict," "objective," "should," or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management's current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company's control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.